Gerd Zettlmeissl has been appointed chairman of the board of ASIT biotech SA, a Belgian developer of allergy therapies, succeeding Béatrice De Vos. Dr Zettlmeissl has been an independent director of ASIT biotech since 2011, and was previously the chief executive of Intercell (now Valneva SE) where he oversaw the global registration of a vaccine against Japanese encephalitis.
Dr Zettlmeissl received his doctorate in biochemistry from the University of Regensburg, Germany, and has completed a post-doctoral fellowship in virology at the Institut Pasteur in Paris.
ASIT biotech announced the appointment on 20 March 2017.
Copyright 2017 Evernow Publishing Ltd